In this light, it was demonstrated that NF-κB inhibitors such as bortezomib can induce immunogenic activation in multiple myeloma cells through the induction of apoptosis and release of damage-associated molecular patterns [98, 99]. This evidence concerns the gene NFKB1 and plasma cell myeloma.